



13 December 2011

Company Announcements Office
Australian Securities Exchanges

Medica and Radiological Society of North America Congress Commercial Update

Medica

Nanosonics is pleased to advise that the international version of the Trophon EPR[®] (N20) was presented at the European Medica exhibition in Dusseldorf, Germany on 16-19 November 2011.

The multiple benefits of the Trophon EPR[®] were highlighted by unprecedented trade orders and commitments from the Company's European dealer network in excess of A\$1.5 million. Equally, there was positive dialogue with a number of the OEM ultrasound manufacturers with GE Healthcare (GEHC) highlighting and demonstrating the Trophon EPR[®] at their own stand.

Radiological Society of North America (RSNA)

The 2011 Trade Show hosted by the RSNA in Chicago in late November saw more than 80,000 attendees and the Trophon EPR[®] (Environmental Probe Reprocessor) was one of the highlights at the vast GE Healthcare exhibition stand. The response from customers (including government), the GEHC sales force and overseas visitors was one of **universal acclaim** for the unique **clean, green** benefits of the Trophon EPR[®] system. Interest in and demand for the Trophon EPR system surpassed all expectations.

A video taken at the recent RSNA exhibition can be viewed at [Nanosonics RSNA 2011](#)

GE Healthcare update

GE Healthcare (GEHC) is the highly regarded leader in the provision of ultrasound to women's health globally. At RSNA GEHC announced that the Trophon EPR[®] is an integral part of its current and long term roadmap in providing the most advanced "clean, green" solutions via its "**healthymagination**" program.

The Chicago RSNA meeting demonstrated that there is a strong pipeline of customer demand for the Trophon EPR[®] leading into 2012 and beyond. The level of international enquiry for markets such as South America, Canada and Asia was also supportive of the attractive global market for the Trophon EPR[®] in presenting a clear and compelling alternative to the use of toxic chemicals in the modern healthcare environment.

GE Healthcare and Nanosonics have reached agreement for Nanosonics to supply a range of commercially attractive accessories for the pre-cleaning of ultrasound probes prior to the use in the Trophon EPR[®] as mandated by regulators and global best practice.

Production update

As previously advised, Nanosonics has now successfully commenced production in its new manufacturing facility. The Company is on track to achieve the additional production capacity, as advised in October 2011.

Nanosonics is now building significant quantities of both the 110v (N10) and 220v (N20) versions of Trophon EPR[®] to service an expanding global market. All of the key manufacturing metrics are trending well and support our envisaged further planned production scale-up in 2012.

The in-field performance of the Trophon EPR[®] (N10 and N20) is well in line with our targets and continues to benefit from the efforts of an outstanding team producing units that are of “world class” quality.

NanoNebulant platform

The successful commercialisation of the Trophon EPR[®] is now being leveraged by Nanosonics in terms of both new commercial applications and as a “regulatory precedent” (predicated device) for a range new NanoNebulant based devices.

Nanosonics has now reached an agreement “in principle” with a major corporation for the funding, development and commercialisation of a new Nanosonics device based the NanoNebulant platform. This new product application will address a significant unmet need in the global market place. Nanosonics is in active discussions to leverage its proprietary technology into a number of applications in healthcare and beyond.

Ron Weinberger
CEO

For more information please contact:
Ron Weinberger, CEO or McGregor Grant, CFO, on 02 8063 1600

About Nanosonics

Nanosonics Limited is developing a portfolio of decontamination products designed to reduce the spread of infection. The Company owns intellectual property relating to a unique disinfection and sterilisation technology which can be suited to a variety of markets.

Initial market applications are designed for the reprocessing of reusable medical instruments. The Company's first product is designed to disinfect Ultrasound Transducers. In parallel with the commercialisation of this product, Nanosonics is also developing other medical applications and exploring opportunities for its proprietary technology in other industries.

For more information about Nanosonics please visit www.nanosonics.com.au